Shaily Engineering Plastics reports strong H1 FY26 financial performance

Shaily Engineering Plastics Ltd. reported impressive unaudited standalone and consolidated financial results for Q2 and H1 FY26, with an earnings call scheduled for November 10, 2025. Consolidated revenue for H1 FY26 increased by 36% to INR 503.3 crores, while standalone revenue grew by 32% to INR 460.7 crores. Consolidated PAT surged by 135% to INR 92.4 crores, and standalone PAT by 231% to INR 77.0 crores. Cash PAT also saw substantial increases, with consolidated figures up 94% to INR 115.8 crores and standalone up 133% to INR 98.8 crores.

The company's operational highlights for Q2 and H1 FY26 include the launch of Shaily Axiom Max – Fixed Dose Pen and the signing of four new healthcare projects. Additionally, 19 new machines were installed as part of a plant expansion. The healthcare segment was the key growth driver, with its revenue increasing by 171% in H1 FY26. Machine utilization rose to 48.2%, and the volume of polymers processed increased by 13.1% in H1 FY26.

The board of directors approved these results during their meeting on November 8, 2025. The statutory auditors, BSR and Co., conducted a limited review of both standalone and consolidated financial statements, confirming compliance with SEBI Listing Regulations, 2015. The company maintains strong credit ratings of CARE A+; Outlook: Stable for long-term facilities and CARE A1 for short-term facilities.